Phase II Trials of Interferons-α and -β in Advanced Sarcomas
- Publication Type:
- Journal Article
- Citation:
- Journal of Interferon Research, 1992, 12 (6), pp. 455 - 458
- Issue Date:
- 1992-01-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
 | 2012000099OK.pdf | 139.54 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Interferons (IFNs)-α and -β were administered to patients with metastatic sarcomas in two different Eastern Cooperative Oncology Group studies. In one study, patients received IFN-α2b, 20 million units/m2 i.v. 5 days/week × 4, then 10 million units s.c. t.i.w. In the second study, patients received IFN-βser 180 million units t.i.w. Of 87 patients evaluable for response, there were three responses in 64 patients (5%) treated with IFN-α-2b and no responses in 23 patients treated with IFN-βser. Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-α2b and 17% of patients receiving IFN-βser Further investigation of IFNs in sarcomas should depend on evidence from preclinical studies demonstrating synergistic effects of IFNs combined with a cytoreductive modality which has proven activity in these malignancies. © 1992, Mary Ann Liebert, Inc. All rights reserved.
Please use this identifier to cite or link to this item: